Camlin Fine Sciences Ltd (CAMLINFINE) — shareholding pattern, promoter holding, financials and share price

About Camlin Fine Sciences Ltd (CAMLINFINE)

Camlin Fine Sciences Ltd operates in the Specialty Chemicals industry, within the Chemicals sector. It trades on the NSE as CAMLINFINE and on the BSE under scrip code 532834. Its ISIN is INE052I01032.

Camlin Fine Sciences is engaged in the Business of Speciality Chemicals.

Camlin Fine Sciences Limited is an India‑headquartered specialty chemicals manufacturer producing antioxidants, aroma ingredients (vanillin/ethyl vanillin), value‑added blends, and performance chemicals with global manufacturing and application laboratories, serving food, feed, nutraceutical, fragrance and industrial end markets across 80+ countries.

Q3 FY26 consolidated revenue was Rs. 4,572 million (up ~6% YoY) while adjusted EBITDA contracted to Rs. 307 million (6.7% margin) and PAT turned negative due to exceptional items, FX adjustments and higher operating costs; management highlighted tariff dynamics, inventory phasing and acquisition costs as primary drivers of near‑term margin pressure.

Listed peers in Specialty Chemicals: Tatva Chintan Pharma Chem Ltd, DDev Plastiks Industries Ltd, NOCIL Ltd, Rossari Biotech Ltd, Bhansali Engineering Polymers Ltd, Nitta Gelatin India Ltd.

Valuation & Returns

10 Jul 2026

At ₹128.4 a share on 10 Jul 2026, Camlin Fine Sciences Ltd (CAMLINFINE) was valued at a price-to-earnings ratio of 89.27x against an industry P/E of 45.11x and a price-to-book of 2.74x on a book value of ₹46.94 per share as of Mar 2025. Solomo computes return on equity of -4.12% and return on capital employed of 2.44% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
89.27x
Industry P/E
45.11x
P/B
2.74x
EPS (TTM)
₹-1.94
Book value / share
₹46.94
ROE
-4.12%
ROCE
2.44%
ROA
-1.84%
Debt / equity
0.76x
Dividend yield
0%
EBITDA margin
9.78%
52-week range
₹96.3 – ₹302.4

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Camlin Fine Sciences Ltd (CAMLINFINE) reported revenue of ₹1,723 crore, net profit of ₹24 crore and earnings per share of ₹1.44. That compares with revenue of ₹1,667 crore and net profit of ₹-158 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹425 crore and net profit ₹86 crore (consolidated).

Consolidated annual results for Camlin Fine Sciences Ltd (CAMLINFINE), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)1,4121,6821,4541,6671,723
Net profit (₹ cr)6040-105-15824
EPS (₹)3.452.96-4.94-7.41.44
Compound annual growth for Camlin Fine Sciences Ltd (CAMLINFINE). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth8.58%8.86%8.95%14.62%
Profit growth----50.76%
Stock price CAGR3%-11%-7%-57%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 48.03% of Camlin Fine Sciences Ltd (CAMLINFINE) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.91% and domestic institutional investors (DII) hold 5.42%. Promoters have pledged 16.2% of their holding. Market capitalisation was ₹2,467 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2010.

Largest disclosed public shareholders in Jun 2026: Icici Prudential Commodities Fund 4.77%, Nirmal Vinod Momaya 1.88%, HUF 1.31%, Ajay Upadhyaya 1.3%, Jagdish N Master 1.01%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202648.03%16.2%0.91%5.42%51.97%
Mar 202648.03%16.6%0.94%7.7%51.97%
Dec 202548.03%10.8%2.12%7.77%51.97%
Sep 202549.08%10.8%2.12%5.48%50.92%
Jun 202549.1%10.8%2.88%4.14%50.9%
Mar 202549.1%10.8%1.47%3.83%50.9%
Dec 202448.02%12.4%0.76%3.39%51.98%
Sep 202448.02%12.4%0.81%4.24%51.98%